Drug treats hepatitis C by targeting body's RNA

03/27/2013 | Science News

A new compound drug could be effective in treating hepatitis C by attacking RNA that allows the virus to gain traction in a patient's body. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially also treat other serious diseases, including cancer. "This is really a revolution in science and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for work on RNA.

View Full Article in:

Science News

Published in Briefs:

SmartBrief Job Listings for Education

Job Title Company Location
San Francisco Unified is Accepting Applications for 2015-16!
San Francisco Unified School District
San Francisco, CA
Director of Professional Services
Engaging Schools, Inc.
Cambridge, MA
Principal at Emerson Academy of Dayton
National Heritage Academies
Dayton, OH
Program Officer, Teacher Development
Knowles Science Teaching Foundation
Moorestown, NJ
Senior Researcher (8194)
American Institute for Researcher
Washington, DC